Octapharma Plasma GmbH operates commercial facilities for whole blood and human plasma donation across Germany and performs collection, filling, freezing, (interim) storage and delivery of the obtained products. The products are sold to customers in the pharmaceutical industry and to healthcare institutions; in the reporting year plasma sales were made almost exclusively to the parent company Octapharma AG under a cost‑plus billing arrangement. As of 31 December 2024 the company operated 21 centres in German cities (e.g. Dessau, Koblenz, Krefeld, Dresden, Mannheim, Berlin‑Spandau) and employed on average 626 staff during the year. Octapharma AG holds 100% of the share capital; following a merger and conversion of capital reserves the share capital was increased to TEUR 500.
- Der Betrieb von Blutspendezentren und von Plasmapheresezentren, - die Entnahme, die Abfüllung, das Einfrieren sowie die (Zwischen-) Lagerung und die Lieferung von menschlichem Blut, Plasma und allen damit in unmittelbarem oder mittelbarem Zusammenhang stehenden Produkten.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 96274 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Hubert Franzaring | Geschäftsführer(in) | Solingen |
| Hendrik Köhler | Geschäftsführer(in) | Monheim |
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 96274 (as of 30 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 13.06.2024 | Company Name Change | Octapharma Plasma GmbH |
| 13.06.2024 | Business Purpose Update | - Der Betrieb von Blutspendezentren und von Plasmapheresezentren, - die Entnahme, die Abfüllung, das Einfrieren sowie die (Zwischen-) Lagerung und die Lieferung von menschlichem Blut, Plasma und allen damit in unmittelbarem oder mittelbarem Zusammenhang stehenden Produkten. |
| 13.06.2024 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 13.06.2024 | Capital Increase | +475.000 € | 500.000 € |
| 27.01.2022 | Share Capital Set | — | 25.000 € |
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 96274 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €69,607,031 | €1,450,871 | €20,606,516 | — |
| 2023 | €20,631,238 | €298,487 | €4,642,191 | — |
| 2022 | €18,185,804 | €264,711 | €2,974,788 | — |
| 2021 | €14,185,363 | -€953,997 | €1,904,063 | — |
| 2020 | €12,362,448 | -€1,908,519 | €2,212,721 | — |
Sign in to download data
Source: German Commercial Register (Handelsregister) Düsseldorf Local Court, HRB 96274 (as of 30 October 2026)
Cerner Health Services Deutschland GmbH
Berlin · Entwicklung und Programmierung von Anwendungssoftware
HOST GmbH Hospital Service + Technik
Frankfurt am Main · Hausmeisterdienste
Eurofins BioPharma Product Testing Munich GmbH
Planegg · Technische, physikalische und chemische Untersuchung
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €28,028,622 | 49.1% |
| Material Costs | €27,374,989 | 47.9% |
| Depreciation | €1,722,223 | 3.0% |
